Global Gynecology Drugs Market, By Therapeutics, By Indication, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2027 – Yahoo Finance

Global Gynecology Drugs Market, By Therapeutics (Non-Hormonal Therapy vs. Hormonal Therapy), By Indication (Contraception, Gynecology Infections, Female Infertility, Postmenopausal disorders, Polycystic Ovary Syndrome, Gynecology Cancer, Endometriosis), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region, Competition Forecast & Opportunities, 2027.
New York, March 10, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "Global Gynecology Drugs Market, By Therapeutics, By Indication, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2027" – https://www.reportlinker.com/p06128265/?utm_source=GNW

The global gynecology drugs market stood at USD14139.56 million in 2021 and is expected to grow at a CAGR of 8.64% to reach USD21395.67 million by 2027. Significant changes in women’s lifestyles and the increasing prevalence of various gynecological cancer and disorders are the primary factors driving the growth of the global gynecology drugs market. Also, the adoption of online sales channels by the gynecology drugs market players and high-end investments by the market players to procure effective gynecology drugs are the other major factors expected to bolster the market growth in the forecast period.
The rise in stress in women and busy lifestyles is giving rise to several diseases, including polycystic ovary syndrome, breast cancer, and menopausal disorders. The government of various countries is making investments and efforts to develop advanced healthcare infrastructure and create health awareness among the women population, which is expected to influence the growth of the global gynecology drugs market in the next five years.
Market players are developing an efficient supply chain and making advanced drugs, which have a higher shelf life and effectiveness to stay ahead.Also, the adoption of online sales channels by the market players is expected to bolster the growth of the global gynecology drugs market.

Many patients have started to buy drugs by using online sales platforms due to the availability of lucrative discounts on the purchase of drugs and the quick delivery facility provided by the market players.
The global gynecology drugs market is segmented into therapeutics, indication, distribution channel, regional distribution, and competitive landscape.Based on distribution channel, the market is divided into retail pharmacies, hospital pharmacies, and online pharmacies.

Retail pharmacies are leading the global market by capturing a market share of 48.39% in 2021 and are expected to maintain their dominance throughout the forecast period, 2023-2027.
Major companies in the market are Amgen Inc., F. Hoffmann La Roche Ltd., Novartis AG, Bayer AG, Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, AstraZeneca Plc, Lupin Limited, Johnson and Johnson, Sanofi SA, Ferring Pharmaceuticals among others.

Years considered for this report:

Historical Years: 2017-2020
Base Year: 2021
Estimated Year: 2022
Forecast Period: 2023-2027

Objective of the Study:

• To analyze the historical growth in the market size of the global gynecology drugs market from 2017 to 2021.
• To estimate and forecast the market size of the global gynecology drugs market from 2022 to 2027 and growth rate until 2027.
• To classify and forecast the global gynecology drugs market is divided into therapeutics, indication, distribution channel, regional distribution, and competitive landscape.
• To identify drivers and challenges for the global gynecology drugs market.
• To examine competitive developments such as expansions, new product launches, mergers, and acquisitions, etc., in the global gynecology drugs market.
• To conduct pricing analysis for the global gynecology drugs market.
• To identify and analyze the profile of leading players operating in global gynecology drugs market.
The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of leading companies across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the companies which could not be identified due to the limitations of secondary research. The analyst examined the companies, distribution channels and presence of all major players operating in the global gynecology drugs market all over the world.
The analyst calculated the global gynecology drugs market size using a bottom-up approach, where data for various regions was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these drugs and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

• Gynecology drugs manufacturers, suppliers, distributors, and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, forums, and alliances related to gynecology drugs market
• Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for industry stakeholders such as gynecology drugs manufacturers, suppliers, distributors, and other stakeholders. The report would enable the stakeholders in strategizing investments and capitalizing on emerging market opportunities.

Report Scope:

In this report, global gynecology drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Global Gynecology Drugs Market, By Therapeutics:
o Non-Hormonal Therapy
o Hormonal Therapy
• Global Gynecology Drugs Market, By Indication:
o Contraception
o Gynecology Infections
o Female Infertility
o Postmenopausal disorders
o Polycystic Ovary Syndrome
o Gynecology Cancers
o Endometriosis
• Global Gynecology Drugs Market, By Distribution Channel:
o Retail Pharmacies
o Hospital Pharmacies
o Online Pharmacies
• Global Gynecology Drugs Market, By Region:
o North America
United States
Canada
Mexico
o Europe
Germany
France
United Kingdom
Italy
Spain
o Asia-Pacific
China
Japan
India
Australia
South Korea
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global gynecology drugs market.

Available Customizations:

With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).
Read the full report: https://www.reportlinker.com/p06128265/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

Yahoo Finance reporter Pras Subramanian details Rivian's miss on both the top and bottom line for Q4 earnings.
If you own shares in Nio (NYSE: NIO), you might want to make volatility your friend. Nio stock sank by double-digit percentages this morning, a day after it jumped double-digits. With today's sharp drop, Nio has now crashed a staggering 34% in just the past month, as of this writing.
Russia is facing effective bankruptcy as soon as Wednesday after the World Bank warned that crippling sanctions have left the Kremlin “mighty close” to a default on its foreign debts.
Bank of America Head of the Research Investment Committee Jared Woodard sits down with Yahoo Finance Live to talk about Amazon's announced 20-for-1 stock split and buyback program, and how tech companies implement these splits to their stock.
The World Bank has warned Russia is “mighty close” to default on sovereign debt. It would mark the first country to suffer a major default in a century. Here are the implications for Russia and the world.
Alibaba (BABA) American depository shares closed at 52-week lows following JD.com's (JD) quarterly print, and amid renewed worries over Chinese ADRs delistings off US exchanges.
These companies are expected to produce rapid growth for sales and earnings, and have high dividend yields well-covered by cash flow.
The SEC named Chinese companies that could face delisting under the Holding Foreign Companies Accountable Act.
Rivian Automotive Inc. stock fell more than 12% late Thursday after the electric-vehicle maker posted a larger-than-expected quarterly loss and said that supply-chain snags and other problems persist.
It was the second quarter in a row that forecasts by the digital-signature company have fallen short of Street estimates and spurred a selloff in the stock.
As of 11 a.m. ET, shares of both e-commerce platform provider Shopify (NYSE: SHOP) and the South American online retail giant MercadoLibre (NASDAQ: MELI) were down by about 6.8%. Meanwhile, Singapore-based Sea Limited (NYSE: SE), which operates the Shopee marketplace in Southeast Asia, was suffering an 8.5% meltdown. Late on Wednesday, for the first time this millennium, Amazon announced a stock split.
After Oracle Corp. Chief Financial Officer Safra Catz offered an in-line forecast and Larry Ellison knowingly laughed when asked about storing TikTok's data in the U.S. on Thursday afternoon, the software company's shares rebounded from a steep after-hours post-earnings decline.
A corporate exodus from Russia in response to its military invasion of Ukraine has seen more than 300 U.S. and multinational companies sever business ties with the country – and the list seems to be growing by the minute. But even as many flee, a number of big-name firms have remained mum.
The e-commerce giant's stock went into a tailspin based on a rumor. But a closer look show it's much ado about nothing.
Yahoo Finance's Pras Submaranian joins the Live show to preview fourth quarter earnings for Rivian.
U.S.-listed Chinese stocks fell across the board as the Securities and Exchange Commission released its first list of Chinese companies that failed to adhere to the newly passed Holding Foreign Companies Accountable Act.
Investors know that the key to profits is in the return – and that means, a willingness to shoulder risk. Risk is relative, of course, and tends to run hand-in-hand with the return potential. Find a stock with a giant return potential, and chances are, you’ve also found one with a higher risk profile. The highest returns usually come along with the lowest share prices. After all, when a stock is priced for just pennies, even a small gain in share price translates into a huge return. Which means
On yet another tough day for tech stocks, with the Nasdaq down 1%, Roblox (NYSE: RBLX) stock fell harder than most. Shares of the online gaming platform plummeted 6.5% through close of trading Thursday, then continued to fall after-hours — and you can blame Jefferies for that. In a note covered by TheFly.com today, Jefferies lowered its price target on Roblox shares by $10, to just $50 a share.
Even after a sustained period of share losses, Amazon (AMZN) stock is still pricey, with one share going for $2,936.35. That, however, is about to come an end. On Wednesday, the tech giant announced it would enact a 20-for-1 stock split, which will go into effect on June 6, should the move be given the go ahead by shareholders in May. If that wasn’t enough to satisfy investors, the company also said it rebought $800 million of shares under its old repurchase authorization and has given the green
Arguing yes is Mark Newton, head of technical strategy at Fundstrat, who notes that while huge rallies are normally to be expected within big downtrends, this move was accompanied by a nearly 5-to-1 breadth. Newton says there isn’t evidence of true capitulation, but the recent negative retail sentiment has helped drive a near-term bottom. By contrast, Dhaval Joshi of BCA Research says stocks may fall further in the short-term.

source